<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment regimens for adult patients with cytomegalovirus (CMV) retinitis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment regimens for adult patients with cytomegalovirus (CMV) retinitis</h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment regimens for adult patients with cytomegalovirus (CMV) retinitis</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Induction</td> <td class="subtitle1">Maintenance*</td> <td class="subtitle1">Laboratory monitoring<sup><span style="font-size: 13px;">¶</span></sup></td> <td class="subtitle1">Dose-limiting toxicity<br/> (percent of patients)</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Primary regimen</td> </tr> <tr class="divider_bottom"> <td class="indent1">Oral valganciclovir<sup><span style="font-size: 13px;">Δ</span></sup></td> <td>900 mg every 12 hours with food for 14-21 days</td> <td>900 mg once per day with food</td> <td>Complete blood count (CBC) twice/week during induction, weekly during maintenance; Serum creatinine monthly</td> <td>Neutropenia<sup>◊</sup>, thrombocytopenia<sup>§</sup>, diarrhea</td> </tr> <tr> <td class="subtitle2_left" colspan="5">If retinal lesions are immediately sight-threatening ADD intravitreal ganciclovir or foscarnet<sup>¥</sup></td> </tr> <tr> <td class="sublist2_start" colspan="5">Ganciclovir</td> </tr> <tr> <td class="indent2">Intraocular implants</td> <td colspan="4">Ganciclovir surgically implanted reservoir is an effective treatment, but is no longer available</td> </tr> <tr> <td class="indent2">Intravitreal injection<sup>¥</sup></td> <td> <p>Single injection<sup>‡</sup>: 2.5 mg per injection (in 0.05 mL volume) in combination with oral valganciclovir<sup>†</sup></p> <p><strong>OR</strong></p> <p>Repeated injections: 2.5 mg per injection (in 0.05 mL volume) weekly for two to three weeks in combination with oral valganciclovir<sup><span style="font-size: 13px;">†</span></sup></p> </td> <td> <p>Oral valganciclovir<sup><span style="font-size: 13px;">†</span></sup></p> <p><strong>OR</strong></p> Intravitreal ganciclovir 2.5 mg (in 0.05 mL volume) per week in settings where systemic therapy is unavailable<sup>**</sup></td> <td>Not applicable</td> <td>Direct retinal toxicity if doses are excessively high</td> </tr> <tr> <td class="sublist2_start" colspan="5">Foscarnet</td> </tr> <tr class="divider_bottom"> <td class="indent2">Intravitreal injection<sup><span style="font-size: 13px;">¥</span></sup></td> <td> <p>Single injection<sup><span style="font-size: 13px;">‡</span></sup>: 2.4 mg per injection in combination with oral valganciclovir<sup><span style="font-size: 13px;">†</span></sup></p> <p><strong>OR</strong></p> Repeated injections: 2.4 mg per injection given twice weekly for up to 4 doses over a period of 7 to 14 days in combination with oral valganciclovir<sup><span style="font-size: 13px;">†</span></sup></td> <td> <p>Oral valganciclovir<sup><span style="font-size: 13px;">†</span></sup></p> </td> <td>Not applicable</td> <td>Direct retinal toxicity if doses are excessively high</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Alternate systemic regimens for patients unable to take oral valganciclovir. If retinal lesions are sight-threatening, ADD intravitreal ganciclovir or foscarnet, as above<sup><span style="font-size: 13px;">¥</span></sup></td> </tr> <tr> <td class="sublist2_start" colspan="5">Intravenous (IV) ganciclovir<sup><span style="font-size: 13px;">Δ</span></sup></td> </tr> <tr> <td class="indent2">Standard dose</td> <td>5 mg/kg IV every 12 hours for 14-21 days</td> <td> <p>5 mg/kg IV per day</p> <p><strong>OR</strong></p> Oral valganciclovir as above</td> <td rowspan="2">Complete blood count (CBC), serum electrolytes twice per week during induction and once weekly during maintenance; serum creatinine monthly</td> <td rowspan="2">Neutropenia (15-50)<sup><span style="font-size: 13px;">◊</span></sup>, thrombocytopenia (5-20)<sup><span style="font-size: 13px;">§</span></sup></td> </tr> <tr> <td class="indent2">High dose (salvage therapy)</td> <td>5 to 7.5 mg/kg IV every 12 hours for 14-21 days</td> <td>10 mg/kg IV per day</td> </tr> <tr> <td class="sublist2_start" colspan="5">Intravenous (IV) foscarnet<span style="font-size: 13px;"><sup>¶¶</sup></span></td> </tr> <tr> <td class="indent2">Standard dose</td> <td>60 mg/kg IV every 8 hours or 90 mg/kg IV every 12 hours for 14-21 days</td> <td> <p>90 mg/kg IV per day</p> <p><strong>OR</strong></p> Oral valganciclovir as above</td> <td>CBC with differential, platelet count, serum creatinine, potassium, magnesium, ionized calcium, phosphorous twice per week during induction, weekly during maintenance; hemoglobin</td> <td rowspan="2">Nephrotoxicity (10-20), infusion-related decreased ionized serum calcium<sup>ΔΔ</sup>, other electrolyte abnormalities, genital ulcers, fluid overload, anemia</td> </tr> <tr> <td class="indent2">High dose (salvage therapy)</td> <td>90 mg/kg IV every 12 hours for 14-21 days</td> <td>120 mg/kg IV per day</td> <td>Same as for standard dose foscarnet</td> </tr> <tr> <td class="indent1">Ganciclovir<sup><span style="font-size: 13px;">Δ</span></sup> and foscarnet<sup>¶¶</sup> (salvage therapy)</td> <td> <p>90 mg foscarnet/kg IV every 12 hours <strong>PLUS either</strong> 5 mg ganciclovir/kg IV per day <strong>or</strong> oral valganciclovir 900 mg per day for 14-21 days</p> <p><strong>OR</strong></p> 5 mg ganciclovir/kg IV every 12 hours (<strong>OR</strong> oral valganciclovir 900 mg twice daily) plus 90 mg foscarnet/kg IV per day for 14-21 days</td> <td>5 mg ganciclovir/kg IV per day (<strong>OR</strong> oral valganciclovir 900 mg daily) plus 90 mg foscarnet/kg IV per day</td> <td>Refer to individual agents above</td> <td>Refer to individual agents above</td> </tr> <tr> <td class="indent1">Cidofovir (IV)<sup>◊◊</sup></td> <td>5 mg/kg IV once per week for 2 weeks</td> <td>5 mg/kg IV once every other week</td> <td>Serum creatinine, urinary protein CBC with differential, platelets, and hepatic transaminases before each infusion</td> <td>Nephrotoxicity (50), proteinuria, neutropenia<sup><span style="font-size: 13px;">◊</span></sup>, decreased intraocular pressure<span style="font-size: 13px;"><sup>§§</sup></span>, iritis<span style="font-size: 13px;"><sup>§§</sup></span>, uveitis<sup><span style="font-size: 13px;">§<span style="font-size: 13px;">§</span></span></sup>, neuropathy; nausea, fever, rash (associated with probenecid)</td> </tr> </tbody></table></div><div class="graphic_lgnd">CMV retinitis should be managed in consultation with an experienced ophthalmologist.</div><div class="graphic_footnotes">* Maintenance with oral valganciclovir is preferred. Considerations for decision to stop maintenance are reviewed in the topic on the treatment of CMV retinitis.<br/>¶<sup> </sup>Monitoring may be less frequent in resource-limited settings. Refer to the topic on treatment of CMV retinitis for a discussion.<br/>Δ The dose of oral valganciclovir or IV ganciclovir should be adjusted for renal insufficiency; for detail, refer to Lexicomp drug monograph included within UpToDate.<br/>◊ Neutropenia is reversible with granulocyte colony-stimulating factor (GCSF) given as adjunctive treatment. Refer to the topic on the treatment of CMV retinitis. <br/>§ Ganciclovir should be stopped for platelet counts &lt;20,000 per microL. Avoid or use caution with other myelosuppressive agents.<br/>¥ The preferred use of intravitreal injections is in the setting of immediately sight threatening lesions in conjunction with systemic therapy. In resource-limited settings, where systemic therapy may not be available, the frequency of dosing is described in the table. A detailed discussion of intravitreal therapy for CMV retinitis is found in the topic on treatment of CMV retinitis.<br/>‡ If systemic therapy is initiated within 24 hours of the initial intravitreal injection, subsequent injections are probably unnecessary.<br/>†<sup> </sup>For patients who cannot take oral valganciclovir, an alternate systemic therapy should be used as described in the table.<br/>** Local treatment alone will not prevent involvement of other eye or additional systems. Refer to the topic on treatment of CMV retinitis.<br/>¶¶ Precise adjustment of foscarnet dose for renal insufficiency is necessary. An infusion pump is used to assure appropriate (ie, 2 hour) infusion time. (For detail refer to Lexicomp drug monograph included with UpToDate). Hydration is recommended to reduce the risk of nephrotoxicity. Infuse 750-1000 mL of normal saline prior to the first infusion of foscarnet to establish diuresis. With subsequent infusions, 750-1000 mL of hydration fluid should be given concurrently with each 90-120 mg/kg infusion of foscarnet.<br/>ΔΔ Symptoms of infusion-related ionized hypocalcemia include tetany, paresthesias, arrhythmia, mental status changes, and headache. If this occurs, the infusion should be slowed. Avoid co-treatment with other nephrotoxic drugs and drugs that can alter serum calcium concentrations (ie, pentamidine). Severe additive toxicity and deaths have been reported.<br/>◊◊ Cidofovir use is contraindicated in patients with pre-existing renal insufficiency or proteinuria. In addition, cidofovir should be avoided in patients with a sulfa allergy because of cross hypersensitivity with probenecid. To decrease cidofovir associated nephrotoxicity, administer 2 g probenecid orally 3 hours before cidofovir infusion and hydrate with 1 L normal saline 1 hour prior to infusion. Administer 1 L normal saline with or immediately after cidofovir infusion. Administer 1 g probenecid orally 2 and 8 hours after infusion is completed. Probenecid is associated with hypersensitivity reactions and intolerance (ie, nausea, vomiting, fever). Dose should be reduced from 5 to 3 mg/kg if serum creatinine level increases by 0.3 to 0.4 mg/dL (26.5 to 35.4 micromol/L) over baseline value. Drug must be discontinued if serum creatinine level increases by &gt;0.5 mg/dL (44 micromol/L) over baseline value or if urinary protein level is &gt;3+. Cidofovir should not be administered concurrently with or within 7 days of other nephrotoxins.<br/>§§ Discontinue cidofovir if intraocular pressure is below 50 percent of baseline value or if uveitis develops that is unresponsive to topical corticosteroids and cycloplegics.</div><div class="graphic_reference">Adapted from:<br/><ol>
<li>Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at <a href="https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/cytomegalovirus-disease?view=full">https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/cytomegalovirus-disease?view=full</a>.</li></ol></div><div id="graphicVersion">Graphic 80535 Version 9.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
